Emalex. Revenue and Competitors

Chicago, IL USA

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Emalex.'s estimated annual revenue is currently $3.4M per year.(i)
  • Emalex.'s estimated revenue per employee is $155,000

Employee Data

  • Emalex. has 22 Employees.(i)
  • Emalex. grew their employee count by 0% last year.

Emalex.'s People

NameTitleEmail/Phone
1
VP, Regulatory Affairs and Quality AssuranceReveal Email/Phone
2
SVP - Legal Affairs and General CounselReveal Email/Phone
3
VP, Chemistry, Manufacturing & ControlsReveal Email/Phone
4
AVP Quality AssuranceReveal Email/Phone
5
Senior Director, Clinical OperationsReveal Email/Phone
6
Sr. Director, GMP Quality AssuranceReveal Email/Phone
7
Chief Business OfficerReveal Email/Phone
8
Sr. Director, Clinical OperationsReveal Email/Phone
9
Sr. Manager, Regulatory OperationsReveal Email/Phone
10
Corporate ControllerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$2.8M18-14%N/AN/A
#2
$0.8M50%N/AN/A
#3
$2M130%N/AN/A
#4
$707.3M285214%$1.1BN/A
#5
$1.7M110%N/AN/A
#6
$32.6M2106%N/AN/A
#7
$2.6M176%N/AN/A
#8
$1.1M7-30%N/AN/A
#9
$1.4M9-10%N/AN/A
#10
$2M138%N/AN/A
Add Company

What Is Emalex.?

Emalex Biosciences, LLC is a biopharmaceutical company dedicated to the development of new treatments for rare and orphan neurological conditions. Ecopipam, its first development candidate, is a novel compound that has been studied as a potential treatment for many central nervous system (CNS) disorders, including pediatric Tourette Syndrome. The latter is a childhood-onset neurodevelopmental condition characterized by motor and vocal tics for which very few safe and effective therapies exist.

keywords:N/A

N/A

Total Funding

22

Number of Employees

$3.4M

Revenue (est)

0%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Emalex. News

2022-03-30 - Emalex Biosciences to Present Positive Results for Pediatric ...

("Emalex"), a biopharmaceutical company focused on developing treatments for central nervous system (CNS) movement disorders and fluency...

2022-03-30 - New Drug May Ease Tourette Tics in Kids, Teens

The new study was funded by Emalex Biosciences, LLC, maker of ecopipam. Gilbert's team randomly selected 149 youths, ages 6 to 17,...

2022-03-30 - New drug ecopipam shows promise for treating Tourette syndrome

The new study was funded by Emalex Biosciences, LLC, maker of ecopipam. RELATED Study: Electric current to the brain may help curb tics in...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$1.4M22-21%$169.9M
#2
$3.9M22-8%N/A
#3
$5M22-8%N/A
#4
$2.2M22-8%N/A
#5
$2.7M220%$12.4M